Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
-
J Dtsch Dermatol Ges · Apr 2010
Case ReportsSuccessful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant.
The bradykinin B2 receptor antagonist icatibant has recently become available for treating hereditary angioedema. Our observations demonstrate icatibant to be effective and safe for the treatment of both, abdominal and cutaneous attacks in a practice setting beyond clinical studies.
-
J Dtsch Dermatol Ges · Feb 2010
Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia.
Postherpetic neuralgia is a frequent adverse event in herpes zoster patients and difficult to treat. Conventional analgetic therapy often fails to reduce the burning pain transmitted by unmyelinated nerve fibers. These nerves express cannabinoid receptors which exert a role in modulation of nociceptive symptoms. Therefore, topical therapy with cannabinoid receptor agonist seems likely to suppress local burning pain. ⋯ Topical cannabinoid receptor agonists are an effective and well-tolerated adjuvant therapy option in postherpetic neuralgia.
-
J Dtsch Dermatol Ges · Dec 2009
Three years after the publication of the German (S3) evidence based psoriasis guidelines--was it worth the effort?
The S3 (evidence-based) psoriasis guidelines were an important milestone in German dermatology. Three years after their publication, a review and evaluation of their success is important. ⋯ The guidelines' website as well as the original publication in the JDDG has been accessed more than 50,000 times. The guidelines' discussion was continued even after its publication and in further publications from within the group a therapeutic algorithm, treatment goals and indicators for the quality of care have been developed.